No Data
No Data
Intensifying competition in the domestic CRO market is eroding profits, BiDe Pharmaceutical claims it will strengthen its overseas market | Direct hit earnings conference
①Due to factors such as the slowdown in investment and financing for innovative drugs, increased competition among CRO companies, BeiDe Medicine's domestic revenue continues to decline, dragging down overall performance and leading to a sharp decrease in net income; ②In contrast, overseas market revenue remains growth, BeiDe Medicine's director, Dai Lan, revealed that there will be corresponding increase in overseas market BD personnel to carry out promotional work in the future.
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Market Cap Increased by CN¥589m, Insiders Receive a 48% Cut
Bide Pharmaceutical (688073.SH): 0.9088 million shares of restricted shares will be unlocked on October 11th.
On September 26, GeLongHui announced that BiDe Pharmaceutical (688073.SH) disclosed that the total number of stocks listed this time is 0.9088 million shares. The date of this stock listing is October 11, 2024.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Bi De Pharmaceutical (688073.SH) released its half-year performance with a net income of 51.8391 million yuan, a year-on-year decrease of 38.15%.
BiDe Pharmaceutical (688073.SH) released its 2024 interim report, with a revenue of 0.532 billion yuan...
No Data
No Data